4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-N-methyl-benzenesulfonamide | 1009121-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-N-methyl-benzenesulfonamide
• 英文别名: 4-(4-chlorophenoxy)-N-(2,5-dibromopyridin-3-yl)-N-methylbenzenesulfonamide
• CAS: 1009121-49-6
• 化学式: C₁₈H₁₃Br₂ClN₂O₃S
• 分子量: 532.64
• InChiKey: BKHUPGIWJZFSEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-N-methyl-benzenesulfonamide 在 双氧水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 4-(4-chlorophenoxy)-N-(2,5-dibromo-1-oxy-pyridin-3-yl)-N-methyl-benzenesulfonamide
  参考文献：
  名称：

  HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

  摘要：

  这项发明提供了一种新颖的杂环衍生物基质金属蛋白酶抑制剂的化学式，以及包含同样化合物的药物组合物，用于治疗通过拮抗基质金属蛋白酶而改善的疾病。该发明还提供了使用即时药物组合物的治疗和预防方法。

  公开号：

  US20080103129A1
• 作为产物：
  描述：

  4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-benzenesulfonamide 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-chlorophenoxy)-N-(2,5-dibromo-pyridin-3-yl)-N-methyl-benzenesulfonamide
  参考文献：
  名称：

  1-Hydroxy-2-pyridinone-based MMP inhibitors: Synthesis and biological evaluation for the treatment of ischemic stroke

  摘要：

  Matrix metalloprotemase-9 (MMP-9) has been implicated in the breakdown of the blood-brain barrier during cerebral ischemia. As a result, inhibition of MMP-9 may have utility as a therapeutic intervention in stroke. Towards this end, we have synthesized a series of 1-hydroxy-2-pyridinones that have excellent in vitro potency in inhibiting MMP-9 in addition to MMP-2. Representative compounds also demonstrate good efficacy in the mouse transient mid-cerebral artery occlusion (tMCAO) model of cerebral ischemia. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.045

文献信息

• US7803793B2
  申请人：——

  公开号：US7803793B2

  公开（公告）日：2010-09-28
• 1-Hydroxy-2-pyridinone-based MMP inhibitors: Synthesis and biological evaluation for the treatment of ischemic stroke
  作者：Yue-Mei Zhang、Xiaodong Fan、Devraj Chakaravarty、Bangping Xiang、Robert H. Scannevin、Zhihong Huang、Jianya Ma、Sharon L. Burke、Prabha Karnachi、Kenneth J. Rhodes、Paul F. Jackson

  DOI：10.1016/j.bmcl.2007.10.045

  日期：2008.1

  Matrix metalloprotemase-9 (MMP-9) has been implicated in the breakdown of the blood-brain barrier during cerebral ischemia. As a result, inhibition of MMP-9 may have utility as a therapeutic intervention in stroke. Towards this end, we have synthesized a series of 1-hydroxy-2-pyridinones that have excellent in vitro potency in inhibiting MMP-9 in addition to MMP-2. Representative compounds also demonstrate good efficacy in the mouse transient mid-cerebral artery occlusion (tMCAO) model of cerebral ischemia. (C) 2007 Elsevier Ltd. All rights reserved.
• HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS
  申请人：Zhang Yue-Mei

  公开号：US20080103129A1

  公开（公告）日：2008-05-01

  This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  这项发明提供了一种新颖的杂环衍生物基质金属蛋白酶抑制剂的化学式，以及包含同样化合物的药物组合物，用于治疗通过拮抗基质金属蛋白酶而改善的疾病。该发明还提供了使用即时药物组合物的治疗和预防方法。